Rucaparib in refractory pleural mesothelioma harboring somatic pathogenic BRCA1 and BRCA2 mutation. A report of two cases
Pleural mesothelioma is a rare disease with few therapeutic options, especially in the first line refractory setting. Targeted agents did not demonstrate a significant clinical benefit in mesothelioma treatment, nevertheless a small group of patients might harbor potentially actionable somatic mutations, as in homologous repair recombination genes. In this paper we report two cases of patients with heavily pretreated pleural mesothelioma that had a relevant clinical benefit with rucaparib treatment based on somatic BRCA 1 and BRCA 2 mutations detected through next generation sequencing.
Authors
- Marika Sculco (ORCID: https://orcid.org/0000-0001-8812-3053)
- F Boccuzzi (ORCID: https://orcid.org/0000-0001-7241-7911)
- Linda Cerbone (ORCID: https://orcid.org/0000-0003-1339-4056)
- Benedetta Del Rio (ORCID: https://orcid.org/0000-0003-3053-6597)
- Irma Dianzani (ORCID: https://orcid.org/0000-0002-9344-3892)
- Antonina Maria De Angelis
- Paolo Bironzo (ORCID: https://orcid.org/0000-0002-2784-5076)
- Luisella Righi (ORCID: https://orcid.org/0000-0002-8927-204X)
- F. Grosso (ORCID: https://orcid.org/0000-0002-9703-2951)
- L Savi (ORCID: https://orcid.org/0009-0009-4698-7895)
- Sara Delfanti (ORCID: https://orcid.org/0000-0002-9862-7340)
- Stefano Meda
- Paola Barbieri
Institutions
- Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
- Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo (IT)
- University of Turin (IT)
Publication Details
- Journal
- Lung Cancer Management
- Published
- 2024-12-04
- DOI
- https://doi.org/10.1080/17581966.2024.2424133
- Citations
- 1
- Primary Topic
- Occupational and environmental lung diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.42